A Multicenter, Clinical Phase II study of FOLFOXIRI with Bevacizumab As First-line Therapy in Patients with Metastatic Colorectal Cancer.
收藏NIAID Data Ecosystem2026-03-08 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2629147
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: [Induction treatment:FOLFOXIRI+BV] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks. [Maintenance treatment:5-FU/LV+BV] BV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.
Primary outcome(s): Progression-free survival (PFS) at 10 months; by investigator-reported measurements.
Study Design: Single arm Non-randomized
创建时间：
2014-06-15
